66 related articles for article (PubMed ID: 38698462)
1. The Role of SCAP/SREBP as Central Regulators of Lipid Metabolism in Hepatic Steatosis.
Chandrasekaran P; Weiskirchen R
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256181
[TBL] [Abstract][Full Text] [Related]
2. Ficolin 3 promotes ferroptosis in HCC by downregulating IR/SREBP axis-mediated MUFA synthesis.
Yuan Y; Xu J; Jiang Q; Yang C; Wang N; Liu X; Piao HL; Lu S; Zhang X; Han L; Liu Z; Cai J; Liu F; Chen S; Liu J
J Exp Clin Cancer Res; 2024 May; 43(1):133. PubMed ID: 38698462
[TBL] [Abstract][Full Text] [Related]
3. ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p.
Yu X; Lin Q; Wu Z; Zhang Y; Wang T; Zhao S; Song X; Chen C; Wang Z; Xu L; Li C; Gao L; Liang X; Yue X; Ma C
J Pathol; 2020 Dec; 252(4):358-370. PubMed ID: 32770671
[TBL] [Abstract][Full Text] [Related]
4. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
[TBL] [Abstract][Full Text] [Related]
5. Stearoyl-CoA Desaturase Promotes Liver Fibrosis and Tumor Development in Mice via a Wnt Positive-Signaling Loop by Stabilization of Low-Density Lipoprotein-Receptor-Related Proteins 5 and 6.
Lai KKY; Kweon SM; Chi F; Hwang E; Kabe Y; Higashiyama R; Qin L; Yan R; Wu RP; Lai K; Fujii N; French S; Xu J; Wang JY; Murali R; Mishra L; Lee JS; Ntambi JM; Tsukamoto H
Gastroenterology; 2017 May; 152(6):1477-1491. PubMed ID: 28143772
[TBL] [Abstract][Full Text] [Related]
6. Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling.
Ma APY; Yeung CLS; Tey SK; Mao X; Wong SWK; Ng TH; Ko FCF; Kwong EML; Tang AHN; Ng IO; Cai SH; Yun JP; Yam JWP
Cancer Res; 2021 Jul; 81(13):3679-3692. PubMed ID: 33975883
[TBL] [Abstract][Full Text] [Related]
7. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARĪ± pathways.
Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
[TBL] [Abstract][Full Text] [Related]
8. Loss of ficolin-3 expression is associated with poor prognosis in patients with hepatocellular carcinoma.
Chen CC; Yu TH; Wu CC; Hung WC; Lee TL; Tang WH; Tsai IT; Chung FM; Lee YJ; Hsu CC
Int J Med Sci; 2023; 20(8):1091-1096. PubMed ID: 37484802
[No Abstract] [Full Text] [Related]
9. The putative role of ferroptosis in gastric cancer: a review.
Wang L; Wang H
Eur J Cancer Prev; 2023 Nov; 32(6):575-583. PubMed ID: 37318883
[TBL] [Abstract][Full Text] [Related]
10. Nodal promotes colorectal cancer survival and metastasis through regulating SCD1-mediated ferroptosis resistance.
Wu T; Wan J; Qu X; Xia K; Wang F; Zhang Z; Yang M; Wu X; Gao R; Yuan X; Fang L; Chen C; Yin L
Cell Death Dis; 2023 Mar; 14(3):229. PubMed ID: 37002201
[TBL] [Abstract][Full Text] [Related]
11. FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway.
Ma D; Liu P; Wen J; Gu Y; Yang Z; Lan J; Fan H; Liu Z; Guo D
Int J Biol Sci; 2023; 19(2):362-376. PubMed ID: 36632465
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan Metabolism Acts as a New Anti-Ferroptotic Pathway to Mediate Tumor Growth.
Liu D; Liang CH; Huang B; Zhuang X; Cui W; Yang L; Yang Y; Zhang Y; Fu X; Zhang X; Du L; Gu W; Wang X; Yin C; Chai R; Chu B
Adv Sci (Weinh); 2023 Feb; 10(6):e2204006. PubMed ID: 36627132
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications.
Stockwell BR
Cell; 2022 Jul; 185(14):2401-2421. PubMed ID: 35803244
[TBL] [Abstract][Full Text] [Related]
14. To curb research misreporting, replace significance and confidence by compatibility: A Preventive Medicine Golden Jubilee article.
Greenland S; Mansournia MA; Joffe M
Prev Med; 2022 Nov; 164():107127. PubMed ID: 35787846
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
